The primary mechanism involves reducing the phosphorylation of eukaryotic translation initiation factor 4E and decreasing c-MYC expression, which may potentially inhibit tumor recurrence and metastasis in patients with KRAS mutations in clinical settings (Knight et al., 2021). The gene discussed is KRAS; the disease is neoplasm.